Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Chemotherapy Alone in Treating Women With Stage IV Breast Cancer
Phase 2 Unknown
Combination Chemotherapy With or Without Epirubicin in Treating Women With Stage I or Stage II Breast Cancer
Phase 3 Completed
2,000 enrolled
Adjuvant Chemotherapy Plus Radiation Therapy in Treating Women With Early-Stage Breast Cancer
Phase 3 Completed
2,250 enrolled
Combination Chemotherapy Compared With Mitoxantrone in Treating Older Patients With Advanced Breast Cancer
Phase 2 Unknown
Tamoxifen Following Combination Chemotherapy in Treating Women With Operable Invasive Breast Cancer
Phase 3 Completed
2,000 enrolled
Tamoxifen, Ovarian Ablation, and/or Combination Chemotherapy in Treating Premenopausal Women With Stage I, Stage II, or Stage IIIA Invasive Breast Cancer
Phase 3 Completed
1,000 enrolled
Tamoxifen With or Without Combination Chemotherapy in Treating Postmenopausal Women With Operable Invasive Breast Cancer
Phase 3 Completed
1,000 enrolled
Standard Chemotherapy Compared With High-Dose Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer
Phase 3 Completed
600 enrolled
Standard Chemotherapy Compared With High-Dose Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Women With Advanced or Inflammatory Breast Cancer
Phase 3 Unknown
300 enrolled
Chemotherapy Plus Surgery in Treating Women With Breast Cancer
Phase 3 Completed
450 enrolled
Combination Chemotherapy in Treating Women With Stage III Breast Cancer
Phase 3 Suspended
Cyclophosphamide, Methotrexate, and Fluorouracil, With or Without Epirubicin Hydrochloride, in Treating Women Who Have Undergone Surgery for Breast Cancer (Group III Closed to New Patients as of 12/7/2009)
Phase 3 Unknown
800 enrolled
Triptorelin in Preventing Early Menopause in Premenopausal Women Who Are Receiving Chemotherapy for Stage I, Stage II, or Stage III Breast Cancer That Has Been Removed By Surgery
Phase 3 Completed
280 enrolled
Cyclophosphamide, Methotrexate, and Prednisolone With or Without Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer
Phase 2 Unknown
70 enrolled
Combination Chemotherapy in Treating Women With Resected Breast Cancer
Phase 2 Unknown
A Pilot Trial of Sequential Chemotherapy With Antimetabolite Induction, High-Dose Alkylating Agent Consolidation With Peripheral Blood Progenitor Cell Support, and Intensification With Paclitaxel and Doxorubicin for Patients With High-Risk Breast Cancer
Phase 2 Completed
55 enrolled